IDEXX Laboratories Tops Q1 Earnings Estimates, Raises Full-Year Guidance
IDEXX Laboratories reported Q1 2026 earnings per share of $3.47, surpassing analyst expectations of $3.41. The company's sales reached $1.14 billion, exceeding the consensus estimate of $1.109 billion. IDEXX also raised its full-year 2026 guidance for both earnings and sales.
IDEXX Laboratories released its Q1 2026 results, reporting earnings per share (EPS) of $3.47, exceeding the analyst consensus estimate of $3.41 . Sales for the quarter reached $1.14 billion, surpassing the consensus forecast of $1.109 billion . These strong results prompted the company to raise its full-year 2026 guidance for both earnings and sales.
The revenue beat was largely driven by higher clinical visits and diagnostic frequency, a trend observed across the healthcare services sector. IDEXX's increased guidance for the remainder of 2026 reflects its confidence in the company's ability to sustain strong growth momentum.
Investors reacted positively to the news, driving shares up 3.35% in premarket trading as of . As a result, the company's stock price movement will be closely watched by market analysts and investors for the remainder of 2026.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis